ICU/NST PharmD @ the intersection of CC, ID, & oncology | always learning @MDAndersonNews | PGY2 CC RPC | @UK_HealthCare R485 | he/him 🏳️🌈
Texas, USA
Joined October 2018
- Tweets434
- Following304
- Followers516
- Likes2.9K
Matt McKenzie retweeted
MD Anderson is proud to be named #1 in the nation for cancer care in @USNews’“Best Hospitals” ranking.
Read more: bit.ly/4lZOVwH
#BestHospitals #EndCancer
ALT Purple background that reads #1 in the nation for cancer care
Matt McKenzie retweeted
ChatGPT less accurate than a pharmacist for DI questions
Job are still safe👍
bit.ly/4kje6Zz
Matt McKenzie retweeted
New @neurocritical care society guideline: Sz ppx for nontraumatic #ICH. Panel suggests AGAINST use of ppx ASM for nontraumatic ICH and if ASM started, rec LEV for ≤ 7 days (as opposed to PHT/fPHT). rdcu.be/d5SQA @NeurocritCareJ @MDNeurocritcare @UMDNeurosurgery
Matt McKenzie retweeted
The OCEANIC-AF randomized trial of the factor XIa inhibitor asundexian was stopped early owing to a higher incidence of stroke or systemic embolism than with apixaban therapy among patients with atrial fibrillation. Full trial results: nej.md/473TRdc
#ESCardio
ALT Graph of the cumulative incidence of stroke or systemic embolism.
Very proud of you @critcarekatie | PGY-Done! Wishing you all the best. Thanks for a great year. @MDAndersonNews @BDeePharmD @emilyhighsmith #pharmICU
Matt McKenzie retweeted
Want to learn how to improve the residency research process and publication rates? Then head over to @ASHPFoundation for my webinar talk on Flipped Research Models at 1 PM CST (2 PM EST). It’s not too late to register! hubs.ly/Q02tRNnr0 #TwitterRx #PharmRes
TODAY! Join us for our live webinar, "Flip It and Research It – Flipped Models for Improved Residency Research," featuring Michael Sirimaturos on May 16, at 2 p.m. Register at hubs.ly/Q02tRP550 #TwitteRx #PharmRes
Twitterless Emily Highsmith liberating us on the C of the ABCDEF bundle #ICULiberation #SCCMSoMe @MDAndersonNews
Matt McKenzie retweeted
🚨NEW POD ALERT🚨
Glycemic Control in the ICU: Part II
Ft. Michael Sirimaturos @MSirimaturos and
Judi Jacobi @judijacobi
2012 v. 2024 scope/PICO ?’s ⚔️
Effect of TGC-FAST 🕙
Role of CDS 🖥️
Becoming guideline panel members ✍️
Important future research topics 🏆
Biggest guideline changes 📰
& much more!
podcasts.apple.com/us/podcas…
open.spotify.com/show/4zYbVR…
pharmacytodose.com/2024/04/1…
Matt McKenzie retweeted
What role do Pharmacists play in immunotherapy? In short, A LOT.
Immunotherapy Part II with Matt McKenzie @mgm485 available now
podcasts.apple.com/us/podcas…
Matt McKenzie retweeted
ICYMI: Immunotherapy Part II featuring Matt McKenzie is available now.
What exactly are CAR-T cells? This and so much more in the full episode
apple.co/3SBTe3I
Matt McKenzie retweeted
Blake Robbins highlights his ⭐️ Star Research abstract, and much more on the 2024 SCCM Congress: Sunday episode.
Available everywhere now: apple.co/42v8rbv
Super humbled to be a part of the pod. Thanks, @PharmacyToDose! #PharmICU
🚨NEW POD ALERT🚨
Immunotherapy Part II
ft. Matt McKenzie @mgm485
Favorite CAR-T cell name 🏅
CRS v. ICANS ⚔️
Treatment considerations 🗒️
Common post-ICI ADE 🫁
Role of PharmD for ADE prevention/treatment 😷
Mattress Mack story 💸
& much more!
Come for the knowledge, stay for Matt’s impressive pronunciation skills 👏
podcasts.apple.com/us/podcas…
open.spotify.com/show/4zYbVR…
pharmacytodose.com/2024/02/0…
#pharmicu #medtwitter #twitterx #hemeonctwitter #cartcell #crs #icans #ici #foamed #some #meded
Listening to our ⭐️ PGY2 CC resident @critcarekatie as she presents her grand rounds on beta lactam-induced neurotoxicity #pharmICU #SCCMSoMe @MDAndersonNews
Great to be back in person @SCCM Congress. Super proud of our @SCCMTXChapter for winning the Chapters Alliance Award. Too many people to thank for making this happen! #sccm2024 #SCCMSoMe
Matt McKenzie retweeted
🎉🥳 congratulations to UKHC CT surgery pharmacist and @UKPharmRes PGY2 RPD @camelpanda for being named a fellow of critical care medicine @SCCM #SCCM2024
Additionally, guidelines give suggested steroid dosing schemes based on timing.
Early ARDS (<24 hr): suggest DEXA-ARDS dosing (PMID: 32043986)
Early ARDS (<72 hr): suggest Meduri dosing (PMID: 9669790)
Unresolving ARDS (7-21 d): suggest Meduri dosing (PMID: 17426195)